Longboard Pharmaceuticals, Inc. focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
| Market Cap | 81.822 Million | Shares Outstanding | 20.558 Million | Avg 30-day Volume | 57.13 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.68 |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -53.695 Million |
| Price to Book Value | 2.5092 | Operating Margin | 0.0 | Enterprise Value | 74.538 Million |
| Current Ratio | 8.689 | EPS Growth | 0 | Quick Ratio | 8.346 |
| 1 Yr BETA | 1.1021 | 52-week High/Low | 10.29 / 3.11 | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 0.0 | Free Cash Flow to Firm (FCFF) TTM | -33.031 Million | Free Cash Flow to Equity (FCFE) TTM | |
| Altman Z-Score | 6.5863 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
0 | 2023-05-25 | 1 | |
|
0 | 2023-05-25 | 1 | |
|
0 | 2023-05-25 | 1 | |
|
0 | 2023-05-25 | 1 | |
|
0 | 2023-05-25 | 1 | |
|
0 | 2023-05-25 | 1 | |
|
KAYE RANDALL CMO |
|
0 | 2023-02-09 | 1 |
|
ROBERTS BRANDI CFO |
|
0 | 2023-02-09 | 1 |
|
0 | 2023-02-09 | 1 | |
|
PERERA PHILIP CMO |
|
95,000 | 2022-02-09 | 0 |
|
3,978,540 | 2021-03-16 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 22:15:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 21:45:03 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 21:15:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 20:45:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 20:15:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 19:45:03 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 19:15:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 18:45:03 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 18:15:03 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 17:45:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 17:15:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 16:45:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 16:15:04 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 15:45:03 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 15:15:03 UTC | 4.1864 | 1.1336 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 14:45:04 UTC | 4.1861 | 1.1339 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 14:15:04 UTC | 4.1861 | 1.1339 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 13:45:04 UTC | 4.1861 | 1.1339 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 13:15:03 UTC | 4.1861 | 1.1339 | 300000 |
| LONGBOARD PHARMACEUTICALS IN LBPH | 2023-11-28 12:45:04 UTC | 4.1861 | 1.1339 | 300000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
